var data={"title":"Isoniazid: Pediatric drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Isoniazid: Pediatric drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/6407?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=isoniazid-drug-information\" class=\"drug drug_general\">see &quot;Isoniazid: Drug information&quot;</a> and <a href=\"topic.htm?path=isoniazid-patient-drug-information\" class=\"drug drug_patient\">see &quot;Isoniazid: Patient drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F5708956\" class=\"block black-box-warn drugH1Div\"><span class=\"drugH1\">ALERT: US Boxed Warning</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Hepatitis:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:2em;\">Severe and sometimes fatal hepatitis associated with isoniazid therapy has been reported and may occur or may develop even after many months of treatment. The risk of developing hepatitis is age related. Approximate case rates by age are as follows: less than 1/1,000 for persons younger than 20 years of age, 3/1,000 for persons in the 20 to 34 year age group, 12/1,000 for persons in the 35 to 49 year age group, 23/1,000 for persons in the 50 to 64 year age group, and 8/1,000 for persons older than 65 years. The risk of hepatitis is increased with daily consumption of alcohol. Precise data to provide a fatality rate for isoniazid-related hepatitis are not available; however, in a US Public Health Service surveillance study of 13,838 persons taking isoniazid, there were 8 deaths among 174 cases of hepatitis.</p>\n        <p style=\"text-indent:-2em;margin-left:2em;\">Therefore, carefully monitor patients given isoniazid and interview patients at monthly intervals. For persons 35 years and older, in addition to monthly symptom reviews, measure hepatic enzymes (specifically, AST and ALT) prior to starting isoniazid therapy and periodically throughout treatment. Isoniazid-associated hepatitis usually occurs during the first 3 months of treatment. Usually, enzyme levels return to normal despite continuance of drug, but, in some cases, progressive liver dysfunction occurs. Other factors associated with an increased risk of hepatitis include daily use of alcohol, chronic liver disease, and injection drug use. A recent report suggests an increased risk of fatal hepatitis associated with isoniazid among women, particularly black and Hispanic women. The risk may also be increased during the postpartum period. Consider more careful monitoring in these groups, possibly including more frequent laboratory monitoring. If abnormalities of liver function exceed 3 to 5 times the upper limit of normal (ULN), strongly consider discontinuation of isoniazid. Liver function tests are not a substitute for a clinical evaluation at monthly intervals or for the prompt assessment of signs or symptoms of adverse reactions occurring between regularly scheduled evaluations. Instruct patients to immediately report signs or symptoms consistent with liver damage or other adverse reactions. These include any of the following: unexplained anorexia, nausea, vomiting, dark urine, icterus, rash, persistent paresthesia of the hands and feet, persistent fatigue, weakness or fever of greater than 3-day duration or abdominal tenderness, especially right upper quadrant discomfort. If these symptoms appear or if signs suggestive of hepatic damage are detected, promptly discontinue isoniazid, because continued use of the drug in these cases has been reported to cause a more severe form of liver damage.</p>\n        <p style=\"text-indent:-2em;margin-left:2em;\">Give patients with tuberculosis who have hepatitis attributed to isoniazid appropriate treatment with alternative drugs. If isoniazid must be reinstituted, do so only after symptoms and laboratory abnormalities have cleared. Restart the drug in very small and gradually increasing doses and withdraw immediately if there is any indication of recurrent liver involvement.</p>\n        <p style=\"text-indent:-2em;margin-left:2em;\">Defer preventive treatment in persons with acute hepatic diseases.</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F184784\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>Dom-Isoniazid;</li>\n      <li>Isotamine;</li>\n      <li>PDP-Isoniazid</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1048065\" class=\"list_set htclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Therapeutic Category</span>\n    <ul>\n      <li>\n        <span class=\"list-set-name\">Antitubercular Agent</span></li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1048057\" class=\"block dos drugH1Div\"><span class=\"drugH1\">Dosing: Usual</span><p>(For additional information <a href=\"topic.htm?path=isoniazid-drug-information\" class=\"drug drug_general\">see &quot;Isoniazid: Drug information&quot;</a>)</p>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Note:</b> Recommendations often change due to epidemiology (resistance) and emerging information; consult CDC and WHO for current recommendations, as appropriate. For patients at risk for isoniazid-induced neuropathy, concomitant pyridoxine is recommended; neuropathy risk factors include pregnancy, breast-feeding infants, and persons with any of the following: HIV, diabetes, malnutrition, alcoholism, chronic renal failure, or advanced age (ATS/CDC/IDSA [Nahid 2016]; WHO 2010; WHO 2014).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pediatric:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Active</b>\n      <b> TB infection</b>\n      <b> (excluding meningitis), treatment (drug susceptible)</b>: <b>Note</b>: Always use as part of a multidrug regimen. Any regimens using less than once daily dosing should administer dosing as directly observed therapy (DOT). Treatment regimens for pulmonary tuberculosis consist of an initial 2-month intensive phase of a 4-drug regimen, followed by a continuation phase of an additional 4 to 7 months of isoniazid and rifampin. Isoniazid frequency and dosing differs depending on treatment regimen selected; consult current drug-sensitive TB guidelines for detailed information (ATS/CDC/IDSA [Nahid 2016]).</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i> ATS/CDC/IDSA Recommendations</i> (ATS/CDC/IDSA [Nahid 2016]):</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">\n      <i>\n        <i> Once daily or 5 times weekly (DOT): </i></i></p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Infants, Children, and Adolescents &lt;15 years, weighing &le;40 kg: Oral, IM: 10 to 15 mg/kg/dose once daily; maximum dose: 300 mg/dose</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Children and Adolescents &lt;15 years weighing &gt;40 kg or Adolescents &ge;15 years: Oral, IM: 5 mg/kg/dose once daily (typical dose: 300 mg)</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">\n      <i>Three-times-weekly DOT: </i>\n      <b>Note:</b> Although suggested dosing based on experience with twice-weekly regimen; experts suggest three-times-weekly regimens are more effective than twice-weekly DOT regimens; three-times-weekly DOT may be used as part of an intensive phase and/or continuation phase dosing regimen; consult guidelines for specific information</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Infants, Children, and Adolescents &lt;15 years, weighing &le;40 kg: Oral, IM: 20 to 30 mg/kg/dose three times weekly; maximum dose: 900 mg/dose; in adolescents, some experts would use 15 mg/kg/dose three times weekly; maximum dose: 900 mg/dose</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Children and Adolescents &lt;15 years weighing &gt;40 kg or Adolescents &ge;15 years: Oral, IM: 15 mg/kg/dose three times weekly (typical dose: 900 mg)</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">\n      <i> Twice-weekly DOT: </i>\n      <b>Note:</b> Regimen not generally recommended; do not use in HIV patients or those with smear-positive and/or cavitary disease. This therapy should only be used following completion of a 2-week intensive phase once-daily (or 5-times-weekly) regimen. Missed doses result in the equivalent of once-weekly dosing which has been shown to be inferior and is associated with treatment failure, relapse, and development of drug resistance.</p>\n    <p style=\"text-indent:-2em;margin-left:12em;\">Infants, Children and Adolescents &lt;15 years, weighing &le;40 kg: Oral, IM: 20 to 30 mg/kg/dose twice weekly; maximum dose: 900 mg/dose</p>\n    <p style=\"text-indent:-2em;margin-left:12em;\">Children and Adolescents &lt;15 years weighing &gt;40 kg or Adolescents &ge;15 years: Oral, IM: 15 mg/kg/dose twice weekly (typical dose: 900 mg)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Latent TB infection (LTBI); treatment (or prevention of primary infection</b>)<b>: Note:</b> Intermittent regimens (eg, once or twice weekly) should be administered by DOT.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Isoniazid monotherapy: </i></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Infants and Children:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Non-HIV-exposed/-positive: Oral: 10 to 20 mg/kg/dose once daily; maximum dose: 300 mg/dose <b>or</b> 20 to 40 mg/kg/dose twice weekly as DOT; maximum dose: 900 mg/dose; treatment duration: 9 months (270 daily doses <b>or</b> 76 twice-weekly doses). <b>Note:</b> Isoniazid monotherapy is the CDC preferred regimen (CDC 2013).</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">HIV-exposed/-positive: Oral: 10 to 15 mg/kg/dose once daily (maximum dose: 300 mg/dose) <b>or</b> 20 to 40 mg/kg/dose (maximum dose: 900 mg/dose) twice weekly as DOT; treatment duration: 9 months (CDC 2013; HHS [OI pediatric 2013])</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Adolescents:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Non-HIV-exposed/-positive: Oral: 10 to 20 mg/kg/dose once daily; maximum dose: 300 mg/dose <b>or</b> 20 to 40 mg/kg/dose twice weekly as DOT; maximum dose: 900 mg/dose; treatment duration: 9 months (270 daily doses <b>or</b> 76 twice weekly doses). <b>Note:</b> Isoniazid monotherapy is the CDC preferred regimen (CDC 2013).</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">HIV-exposed/-positive: Oral: 300 mg once daily <b>or</b> 900 mg twice weekly as DOT; treatment duration: 9 months (HHS [OI adult 2015])</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Isoniazid combination therapy:</i> <b>Note:</b> Should not be used in individuals presumed to be infected with isoniazid or rifampin resistant strains of TB.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Rifapentine combination:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Non-HIV-exposed/-positive: Children 2 to 11 years (not preferred) and Children &ge;2 years and Adolescents: Oral: 15 mg/kg/dose once weekly of isoniazid as DOT for 3 months (12 doses), round dose up to nearest 50 or 100 mg; maximum dose: 900 mg/dose (CDC 2013).<b> Note:</b> For children 2 to 11 years, use of this regimen should be limited to situations where completion of the 9-month regimen is unlikely and the hazard of tuberculosis is great (CDC 2013).</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">HIV-exposed/-positive: Children &ge;12 years and Adolescents who are otherwise healthy and not on antiretroviral medication: Oral: 15 mg/kg/dose once weekly of isoniazid for 3 months (12 doses), round dose up to nearest 50 or 100 mg; maximum dose: 900 mg/dose (CDC 2013)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Rifampin combination: HIV-exposed/-positive: Children: Oral: 10 to 15 mg/kg/dose once daily; maximum dose: 300 mg/dose; treatment duration: 3 to 4 months (HHS [OI pediatric 2013])</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Adult:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b> Tuberculosis, active (drug susceptible):</b> Oral, IM: <b>Note:</b> Always administer in combination with other antitubercular drugs. Concomitant pyridoxine is also recommended in any patient at risk for neuropathy (eg, patients with HIV infection, diabetes, alcoholism, nutritional deficiency, chronic renal failure, advanced age) (Nahid 2016).</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">ATS/CDC/IDSA drug-susceptible tuberculosis guideline recommendations (Nahid 2016):</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">\n      <i> Dosing: </i></p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Once-daily therapy: 5 mg/kg/dose (usual dose: 300 mg) once daily. <b>Note: </b>The preferred frequency of administration is once daily during the intensive and continuation phases; however, 5 days/week administration by directly observed therapy (DOT) is an acceptable alternative.</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Three-times-weekly DOT: 15 mg/kg/dose (usual dose: 900 mg) administered three times weekly</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Twice-weekly DOT: 15 mg/kg/dose (usual dose: 900 mg) administered twice weekly</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Once-weekly DOT: 15 mg/kg/dose (usual dose: 900 mg) administered once weekly</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">\n      <i>Regimens:</i> Treatment regimens for pulmonary tuberculosis and tuberculous meningitis consist of an initial 2 month phase of a 4-drug regimen, followed by a continuation phase of an additional 4 to 7 months of isoniazid and rifampin for pulmonary tuberculosis and a continuation phase of an additional 7 to 10 months of isoniazid and rifampin for tuberculous meningitis (optimal duration is not defined although continuation phase must continue for a minimum of 7 additional months). Adjunctive corticosteroid therapy (eg, dexamethasone, prednisolone) tapered over 6 to 8 weeks is also recommended for tuberculous meningitis. Isoniazid frequency and dosing differs depending on treatment regimen selected; consult current drug-sensitive TB guidelines (Nahid 2016).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Tuberculosis, latent infection (LTBI):</b> Oral, IM: <b>Note:</b> Concomitant administration of pyridoxine 10 to 50 mg daily is recommended in malnourished patients or those prone to neuropathy (eg, patients with HIV-infection, diabetes, or chronic alcohol abusers).</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>CDC recommendations</i> (CDC 2013):</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Non-HIV-exposed/-infected: 5 mg/kg (maximum: 300 mg/dose) once daily for 6 or 9 months or 15 mg/kg (maximum: 900 mg/dose) twice weekly for 6 or 9 months. <b>Note:</b> Nine months is optimal; 6 months may be considered to reduce costs of therapy and improve adherence.</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">HIV-exposed/-infected patients who are receiving antiretroviral therapy: 5 mg/kg (maximum: 300 mg/dose) once daily for 9 months or 15 mg/kg (maximum: 900 mg per dose) twice weekly for 9 months. <b>Note:</b> LTBI treatment is recommended in HIV-infected patients testing positive for LTBI (but have no evidence of TB disease and no history of treatment for active or LTBI) <b>or</b> in HIV-infected close contacts of anyone who has infectious TB (regardless of screening tests for LTBI). LTBI treatment is not associated with clinical benefit or recommended in HIV-infected patients who are anergic and who have not had recent contact with anyone with infectious TB (HHS [OI adult 2015]).</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Alternate regimen: 15 mg/kg/dose (maximum: 900 mg) once weekly in combination with rifapentine for 12 weeks. <b>Note:</b> The rifapentine-containing regimen may only be used in patients who are not pregnant and/or not expecting to become pregnant; if used in HIV-infected patients, it may only be used in otherwise healthy HIV-infected patients <b>not</b> receiving antiretroviral therapy (ART) (high risk of drug-drug interactions with rifapentine) (CDC 2013; HHS [adult] 2015).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Dosing adjustment in renal impairment:</b> Dialyzable. No dosage adjustment needed in patients with renal impairment (ATS/CDC/IDSA 2016; WHO 2010).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Dosing adjustment in hepatic impairment:</b> There are no dosage adjustments provided in the manufacturer's labeling; however, use with caution, may accumulate and additional liver damage may occur in patients with preexisting liver disease. Contraindicated in patients with acute liver disease or previous isoniazid-associated hepatic injury. For ALT or AST &gt;3 times the ULN: Discontinue or temporarily withhold treatment. Treatment with isoniazid for latent tuberculosis infection should be deferred in patients with acute hepatic diseases.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F184755\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution, Injection: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 100 mg/mL (10 mL)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Syrup, Oral: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 50 mg/5 mL (473 mL)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Tablet, Oral: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 100 mg, 300 mg</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F184739\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Availability (US)</span>\n    <p style=\"text-indent:0em;display:inline\">Yes</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1048069\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Oral: Administer on an empty stomach (1 hour before or 2 hours after meals with water)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Parenteral: IM: May be used for patients who are unable to either take or absorb oral therapy. Inject deep IM into a large muscle mass.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F184778\" class=\"block sts drugH1Div\"><span class=\"drugH1\">Storage/Stability</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tablet: Store at 20&deg;C to 25&deg;C (68&deg;F to 77&deg;F). Protect from moisture and light.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Oral solution: Store at 15&deg;C to 30&deg;C (59&deg;F to 86&deg;F). Protect from light.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Injection: Store at 20&deg;C to 25&deg;C (68&deg;F to 77&deg;F). Protect from light. Isoniazid injection may crystallize at low temperatures. If this occurs, warm the vial to room temperature before use to redissolve the crystals.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1048068\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:0em;display:inline\">Treatment of susceptible active mycobacterial infection due to <i>M. tuberculosis </i>(TB) (FDA approved in children and adults); treatment of latent TB infection (LTBI) caused by <i>M. tuberculosis</i> (also referred to as prophylaxis or preventive therapy) (FDA approved in infants, children, and adults)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F3271336\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">International issues:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">Hydra [Japan] may be confused with Hydrea brand name for hydroxyurea [U.S., Canada, and multiple international markets]</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F184829\" class=\"block arm drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cardiovascular: Vasculitis</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Central nervous system: Brain disease, memory impairment, paresthesia, peripheral neuropathy, psychosis, seizure</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dermatologic: Skin rash (morbilliform, maculopapular, pruritic, or exfoliative), toxic epidermal necrolysis</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Endocrine &amp; metabolic: Gynecomastia, hyperglycemia, metabolic acidosis, pellagra, pyridoxine deficiency</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Gastrointestinal: Epigastric distress, nausea, pancreatitis, vomiting</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Genitourinary: Bilirubinuria</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hematologic &amp; oncologic: Agranulocytosis, anemia (sideroblastic, hemolytic, or aplastic), eosinophilia, lymphadenopathy, thrombocytopenia</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hepatic: Hepatitis (risk increases with age), hyperbilirubinemia, increased serum transaminases (mild and transient), jaundice</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Immunologic: DRESS syndrome</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Neuromuscular &amp; skeletal: Lupus-like syndrome, rheumatic disease</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ophthalmic: Optic atrophy, optic neuritis</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Miscellaneous: Fever</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Rare but important or life-threatening: Hepatotoxicity (idiosyncratic) (Chalasani 2014)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F184763\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:0em;display:inline\">Hypersensitivity to isoniazid or any component of the formulation, including drug-induced hepatitis; acute liver disease; previous history of hepatic injury during isoniazid therapy; previous severe adverse reaction (drug fever, chills, arthritis) to isoniazid</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F184743\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hepatitis: <b>[US Boxed Warning]: Severe and sometimes fatal hepatitis may occur; usually occurs within the first 3 months of treatment, although may develop even after many months of treatment.</b> The risk of developing hepatitis is age-related, although isoniazid-induced hepatotoxicity has been reported in children; daily ethanol consumption, chronic liver disease, or injection drug use may also increase the risk. Patients given isoniazid must be monitored carefully and interviewed at monthly intervals. Fatal hepatitis associated with isoniazid may be increased in women (particularly black and Hispanic and in any woman in the postpartum period). Closer monitoring may be considered in these groups. Patients &ge;35 years should also have AST and ALT measured at baseline and periodically throughout treatment. Patients must report any prodromal symptoms of hepatitis, such as fatigue, paresthesias of hands and feet, weakness, dark urine, rash, anorexia, nausea, fever &gt;3 days&rsquo; duration, and/or abdominal pain (especially right upper quadrant discomfort), icterus, or vomiting. Patients should be instructed to immediately hold therapy if any of these symptoms occur, and contact their prescriber. If abnormalities of liver function exceed 3 to 5 times the upper limit of normal (ULN), strongly consider discontinuation of isoniazid. If isoniazid must be reinstituted, wait for symptoms and laboratory abnormalities to resolve and use very small and gradual increasing doses, withdrawing therapy immediately if an indication of recurrent hepatic involvement.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Peripheral neuropathies: Pyridoxine supplementation is recommended in individuals at risk for development of peripheral neuropathies (eg, HIV infection, nutritional deficiency, diabetes, alcoholism, chronic renal failure, advanced age) (Nahid 2016).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hepatic impairment: Use with caution in patients with hepatic impairment; contraindicated in patients with acute liver disease or previous isoniazid-associated hepatic injury. Treatment with isoniazid for latent tuberculosis infection (LTBI) should be deferred in patients with acute hepatic diseases.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Renal impairment: Use with caution in patients with severe renal impairment.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concurrent drug therapy issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Other warnings/precautions:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Appropriate use: Multidrug regimens should be utilized for the treatment of active tuberculosis to prevent the emergence of drug resistance.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Monitoring:  Use should be carefully monitored in the following groups: Daily users of alcohol, active chronic liver disease, severe renal dysfunction, age &gt;35 years, concurrent use of any chronically administered drug, history of previous isoniazid discontinuation, existence of or conditions predisposing to peripheral neuropathy, pregnancy, injection drug use, women in minority groups (particularly postpartum), HIV seropositive patients.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F184818\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Substrate</b> of CYP2E1 (major); <b>Note:</b> Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential; <b>Inhibits</b> CYP2A6 (moderate), CYP2C9 (weak), CYP2E1 (moderate), CYP3A4 (weak); <b>Induces</b> CYP2E1 (weak/moderate)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F184748\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=13393&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Acetaminophen: Isoniazid may enhance the adverse/toxic effect of Acetaminophen. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">ARIPiprazole: CYP3A4 Inhibitors (Weak) may increase the serum concentration of ARIPiprazole.  Management: Monitor for increased aripiprazole pharmacologic effects. Aripiprazole dose adjustments may or may not be required based on concomitant therapy and/or indication. Consult full interaction monograph for specific recommendations.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Artesunate: CYP2A6 Inhibitors may decrease serum concentrations of the active metabolite(s) of Artesunate. CYP2A6 Inhibitors may increase the serum concentration of Artesunate. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">BCG (Intravesical): Antibiotics may diminish the therapeutic effect of BCG (Intravesical). <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">BCG Vaccine (Immunization): Antibiotics may diminish the therapeutic effect of BCG Vaccine (Immunization). <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CarBAMazepine: May enhance the hepatotoxic effect of Isoniazid. Isoniazid may increase the serum concentration of CarBAMazepine.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Chlorzoxazone: Isoniazid may increase the serum concentration of Chlorzoxazone. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cholera Vaccine: Antibiotics may diminish the therapeutic effect of Cholera Vaccine. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Corticosteroids (Systemic): May decrease the serum concentration of Isoniazid.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CycloSERINE: Isoniazid may enhance the adverse/toxic effect of CycloSERINE. Specifically, CNS toxicity may be enhanced. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CYP2A6 Substrates (High risk with Inhibitors): CYP2A6 Inhibitors (Moderate) may decrease the metabolism of CYP2A6 Substrates (High risk with Inhibitors). <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CYP2E1 Substrates (High risk with Inhibitors): CYP2E1 Inhibitors (Moderate) may decrease the metabolism of CYP2E1 Substrates (High risk with Inhibitors). <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cyproterone: May decrease the serum concentration of CYP2E1 Substrates (High risk with Inducers).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Disulfiram: May enhance the adverse/toxic effect of Isoniazid. Disulfiram may increase the serum concentration of Isoniazid.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dofetilide: CYP3A4 Inhibitors (Weak) may increase the serum concentration of Dofetilide. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dolutegravir: May enhance the adverse/toxic effect of Isoniazid.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ethionamide: May increase the serum concentration of Isoniazid.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Flibanserin: CYP3A4 Inhibitors (Weak) may increase the serum concentration of Flibanserin. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Fosphenytoin: Isoniazid may increase the serum concentration of Fosphenytoin.  Management: Consider alternatives. If concomitant therapy cannot be avoided, monitor for increased phenytoin concentrations/effects with isoniazid initiation/dose increase, or decreased concentrations/effects with isoniazid discontinuation/dose decrease.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Itraconazole: Isoniazid may decrease the serum concentration of Itraconazole. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ketoconazole (Systemic): Isoniazid may decrease the serum concentration of Ketoconazole (Systemic). <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Lactobacillus and Estriol: Antibiotics may diminish the therapeutic effect of Lactobacillus and Estriol. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Levodopa: Isoniazid may diminish the therapeutic effect of Levodopa. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Lomitapide: CYP3A4 Inhibitors (Weak) may increase the serum concentration of Lomitapide.  Management: Patients on lomitapide 5 mg/day may continue that dose. Patients taking lomitapide 10 mg/day or more should decrease the lomitapide dose by half. The lomitapide dose may then be titrated up to a max adult dose of 30 mg/day.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">NiMODipine: CYP3A4 Inhibitors (Weak) may increase the serum concentration of NiMODipine. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Phenytoin: Isoniazid may increase the serum concentration of Phenytoin.  Management: Consider alternatives. If concomitant therapy cannot be avoided, monitor for increased phenytoin concentrations/effects with isoniazid initiation/dose increase, or decreased concentrations/effects with isoniazid discontinuation/dose decrease.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pimozide: CYP3A4 Inhibitors (Weak) may increase the serum concentration of Pimozide. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Propacetamol: Isoniazid may enhance the hepatotoxic effect of Propacetamol. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Prothionamide: Isoniazid may increase the serum concentration of Prothionamide. Prothionamide may increase the serum concentration of Isoniazid.  Management: Consider a prothionamide dose reduction and do not exceed 500 mg per day if combined with isoniazid. Additionally, monitor for increased isoniazid toxicities and ensure pyridoxine supplementation is provided if these drugs are combined.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Rifamycin Derivatives: May enhance the hepatotoxic effect of Isoniazid. Even so, this is a frequently employed combination regimen.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Safinamide: May enhance the adverse/toxic effect of Isoniazid. Specifically, there is an increased risk for hypertension.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sodium Picosulfate: Antibiotics may diminish the therapeutic effect of Sodium Picosulfate.  Management: Consider using an alternative product for bowel cleansing prior to a colonoscopy in patients who have recently used or are concurrently using an antibiotic.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tegafur: CYP2A6 Inhibitors (Moderate) may decrease serum concentrations of the active metabolite(s) of Tegafur. Specifically, CYP2A6 inhibitors may inhibit the conversion of tegafur into its active metabolite, 5-fluorouracil. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Theophylline Derivatives: Isoniazid may increase the serum concentration of Theophylline Derivatives. <b> Exceptions: </b>Dyphylline.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Typhoid Vaccine: Antibiotics may diminish the therapeutic effect of Typhoid Vaccine. Only the live attenuated Ty21a strain is affected.  Management: Vaccination with live attenuated typhoid vaccine (Ty21a) should be avoided in patients being treated with systemic antibacterial agents.  Use of this vaccine should be postponed until at least 3 days after cessation of antibacterial agents.<i> Risk D: Consider therapy modification</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F184779\" class=\"block foi drugH1Div\"><span class=\"drugH1\">Food Interactions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Administration with food significantly reduces bioavailability. Management: Avoid administration with food.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Isoniazid may decrease folic acid absorption and alters pyridoxine metabolism. Management: Increase dietary intake of folate, niacin, and magnesium.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tyramine-containing food: Isoniazid has weak monoamine oxidase inhibiting activity and may potentially inhibit tyramine metabolism. Several case reports of mild reactions (flushing, palpitations, headache, mild increase in blood pressure, diaphoresis) after ingestion of certain types of cheese or red wine, have been reported (Self, 1999; Toutoungi, 1985). Management: Manufacturer&rsquo;s labeling recommends avoiding tyramine-containing foods (eg, aged or matured cheese, air-dried or cured meats including sausages and salamis; fava or broad bean pods, tap/draft beers, Marmite concentrate, sauerkraut, soy sauce, and other soybean condiments). However, the clinical relevance of the tyramine reaction for the vast majority of patients receiving isoniazid has been questioned due to isoniazid&rsquo;s weak MAO inhibition and the relatively few published case reports of the interaction. Although not fully investigated, it has been proposed that the reaction has a genetic component and may only be significant in poor or intermediate acetylators since isoniazid is primarily inactivated by acetylation (DiMartini, 1995; Toutoungi, 1985).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Histamine-containing food: Isoniazid may also inhibit diamine oxidase resulting in headache, sweating, palpitations, flushing, diarrhea, itching, wheezing, dyspnea or hypotension to histamine-containing foods (eg, skipjack, tuna, saury, other tropical fish). Management: Manufacturer&rsquo;s labeling recommends avoiding histamine-containing foods; corticosteroids and antihistamines may be administered if histamine intoxication occurs (Miki 2005).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F184751\" class=\"block prf drugH1Div\"><span class=\"drugH1\">Pregnancy Risk Factor</span>\n    <p style=\"text-indent:0em;display:inline\">C (<a href=\"image.htm?imageKey=DRUG%2F50021\" class=\"graphic graphic_table\">show table</a>)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F184767\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Adverse events were observed in some animal reproduction studies.  Isoniazid crosses the human placenta. Due to the risk of tuberculosis to the fetus, treatment is recommended when the probability of maternal disease is moderate to high. Drug-susceptible TB guidelines recommend isoniazid as part of the initial treatment regimen. Isoniazid is also recommended for the treatment of TB in pregnant women with HIV-coinfection. Pyridoxine supplementation is recommended (Nahid 2016). Due to biologic changes during pregnancy and early postpartum, pregnant women may have increased susceptibility to tuberculosis infection or reactivation of latent disease (Mathad 2012).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1048064\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">Baseline and periodic (more frequently in patients with higher risk for hepatitis) liver function tests (ALT and AST); sputum cultures monthly (until two consecutive negative cultures reported); monitoring for prodromal signs of hepatitis</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">LTBI therapy: American Thoracic Society/Centers for Disease Control (ATS/CDC) recommendations: Monthly clinical evaluation, including brief physical exam for adverse events. Use should be carefully monitored in the following groups: Daily users of alcohol, active chronic liver disease, severe renal dysfunction, age &gt;35 years, concurrent use of any chronically administered drug, history of previous isoniazid discontinuation, existence of or conditions predisposing to peripheral neuropathy, pregnancy, injection drug use, women in minority groups (particularly postpartum), and HIV seropositive patients. AST and ALT should be obtained at baseline and at least monthly during LTBI use. Discontinue temporarily or permanently if liver function tests &gt;3 to 5 times ULN. Routine, periodic monitoring is recommended for any patient with an abnormal baseline or at increased risk for hepatotoxicity.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F184742\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Isoniazid inhibits the synthesis of mycoloic acids, an essential component of the bacterial cell wall. At therapeutic levels isoniazid is bacteriocidal against actively growing intracellular and extracellular <i>Mycobacterium tuberculosis</i> organisms.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F184762\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics (Adult data unless noted)</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Note:</b> Isoniazid is primarily metabolized by acetylation and dehydrazination. Rate of acetylation is genetically determined.  Approximately 50% of blacks and whites are &ldquo;slow inactivators&rdquo; and the rest are &ldquo;rapid inactivators&rdquo;. The large majority of Eskimo and Asian patients are &ldquo;rapid inactivators&rdquo;. Acetylation rate does not significantly alter the effectiveness, but slow acetylation may lead to higher blood levels and possibly an increase in adverse effects.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">Absorption: Oral, IM: Rapid and complete; food reduces rate and extent of absorption</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Distribution: All body tissues and fluids including CSF</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Protein binding: 10% to 15%</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Metabolism: Hepatic to acetylisoniazid with decay rate determined genetically by acetylation phenotype; undergoes further hydrolysis to isonicotinic acid and acetylhydrazine</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Half-life: May be prolonged in patients with impaired hepatic function or severe renal impairment</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Fast acetylators: 30 to 100 minutes</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Slow acetylators: 2 to 5 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Time to peak, serum: 1 to 2 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Excretion: Urine (75% to 95% as unchanged drug and metabolites); small amounts excreted in feces and saliva</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F184761\" class=\"block exp drugH1Div\"><span class=\"drugH1\">Extemporaneous Preparations</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Note:</b> Commercial oral solution is available (50 mg/5 mL)</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">A 10 mg/mL oral suspension may be made with tablets, purified water, and sorbitol. Crush ten 100 mg tablets in a mortar and reduce to a fine powder. Add 10 mL of purified water and mix to a uniform paste. Mix while adding sorbitol in incremental proportions to <b>almost</b> 100 mL; transfer to a graduated cylinder, rinse mortar with sorbitol, and add quantity of sorbitol sufficient to make 100 mL (do not use sugar-based solutions). Label &quot;shake well&quot; and &quot;refrigerate&quot;. Stable for 21 days refrigerated.</p>\n    <div class=\"reference\">Nahata MC, Pai VB, and Hipple TF, <i>Pediatric Drug Formulations</i>, 5th ed, Cincinnati, OH: Harvey Whitney Books Co, 2004.</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F184766\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Isoniazid Injection)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">100 mg/mL (10 mL): $352.06</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Syrup</b> (Isoniazid Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">50 mg/5 mL (473 mL): $408.80</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablets</b> (Isoniazid Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">100 mg (100): $14.75</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">300 mg (100): $40.10</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F184770\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Antimic (TH);</li>\n      <li>Cemidon (ES);</li>\n      <li>Curazid Forte (PH);</li>\n      <li>Dianicotyl (GR);</li>\n      <li>Eutizon (HR);</li>\n      <li>Fluodrazin (BR);</li>\n      <li>Hidrazida (PT);</li>\n      <li>Hydra (JP);</li>\n      <li>Hydrazin (TW);</li>\n      <li>I.N.H. (ZW);</li>\n      <li>INH Agepha (AT);</li>\n      <li>INH Lannacher (AT);</li>\n      <li>INH Waldheim (AT);</li>\n      <li>Iscotin (TW);</li>\n      <li>Iso (BD);</li>\n      <li>Isokin (IN);</li>\n      <li>Isonex (ID, IN);</li>\n      <li>Isoniac (AR);</li>\n      <li>Isoniazid (AU, NZ);</li>\n      <li>Isoniazid Atlantic (HK);</li>\n      <li>Isoniazid &rdquo;Dak&rdquo; (DK);</li>\n      <li>Isoniazid &rdquo;Oba&rdquo; (DK);</li>\n      <li>Isoniazide Drank FNA (NL);</li>\n      <li>Isoniazidum (PL);</li>\n      <li>Isonicid (HN);</li>\n      <li>Isonid (BD);</li>\n      <li>Isozid (DE);</li>\n      <li>Isozide (VN);</li>\n      <li>Nicizina (AR);</li>\n      <li>Nicotibine (BE, IL, LU);</li>\n      <li>Nicozid (IT);</li>\n      <li>Nidrazid (CZ);</li>\n      <li>Nisozid (BD);</li>\n      <li>Nydrazide (PK);</li>\n      <li>Pycazide (GB);</li>\n      <li>Rimicid (BG);</li>\n      <li>Rimifon (CH, FR, GB, QA);</li>\n      <li>Sheng Jun (CN);</li>\n      <li>Solonex (CO, LK);</li>\n      <li>Tebilon (AT);</li>\n      <li>Tibinide (SE);</li>\n      <li>Tubilysin (FI);</li>\n      <li>Valifol (MX);</li>\n      <li>Yuhan-Zid (KR)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    Centers for Disease Control and Prevention (CDC). Latent tuberculosis infection: a guide for primary health care providers. Available at http://www.cdc.gov/tb/publications/ltbi/pdf/TargetedLTBI.pdf. 2013. Accessed May 9, 2014.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Centers for Disease Control and Prevention (CDC), &quot;Severe Isoniazid-Associated Liver Injuries Among Persons Being Treated for Latent Tuberculosis Infection - United States, 2004-2008,&quot; <i>MMWR Morb Mortal Wkly Rep</i>, 2010, 59(8):224-9. Available at <a href=\"http://www.cdc.gov/mmwr/preview/mmwrhtml/mm5908a3.htm\" target=\"_blank\">http://www.cdc.gov/mmwr/preview/mmwrhtml/mm5908a3.htm</a>.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/isoniazid-pediatric-drug-information/abstract-text/20203555 /pubmed\" target=\"_blank\" id=\"20203555 \">20203555 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Centers for Disease Control and Prevention (CDC), &quot;Treatment of Tuberculosis,&quot; <i>MMWR Recomm Rep</i>, 2003, 52(RR-11):1-77.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/isoniazid-pediatric-drug-information/abstract-text/12836625/pubmed\" target=\"_blank\" id=\"12836625\">12836625</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Centers for Disease Control and Prevention (CDC), &quot;Update: Adverse Event Data and Revised American Thoracic Society/CDC Recommendations Against the Use of Rifampin and Pyrazinamide for Treatment of Latent Tuberculosis Infection-United States, 2003,&quot;  <i>MMWR Morb Mortal Wkly Rep</i>, 2003, 52(31):735-9.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/isoniazid-pediatric-drug-information/abstract-text/12904741 /pubmed\" target=\"_blank\" id=\"12904741 \">12904741 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    DiMartini A. Isoniazid, tricyclics and the &quot;cheese reaction&quot;. <i>Int Clin Psychopharmacol</i>. 1995;10(3):197-198.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/isoniazid-pediatric-drug-information/abstract-text/8675973/pubmed\" target=\"_blank\" id=\"8675973\">8675973</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    HHS Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. <a href=\"http://www.aidsinfo.nih.gov/ContentFiles/AdultandAdolescentGL.pdf\" target=\"_blank\">http://www.aidsinfo.nih.gov/ContentFiles/AdultandAdolescentGL.pdf</a>. Updated April 8, 2015. Accessed July 8, 2015.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    HHS Panel on Opportunistic Infections in HIV-Exposed and HIV-Infected Children. Guidelines for the prevention and treatment of opportunistic infections in HIV-exposed and HIV-infected children. Department of Health and Human Services. November 2013. Available at <a href=\"http://aidsinfo.nih.gov/contentfiles/lvguidelines/oi_guidelines_pediatrics.pdf\" target=\"_blank\">http://aidsinfo.nih.gov/contentfiles/lvguidelines/oi_guidelines_pediatrics.pdf</a>.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    HHS Panel on Opportunistic Infections in HIV-Infected Adults and Adolescents. Guidelines for the prevention and treatment of opportunistic infections in HIV-infected adults and adolescents: recommendations from the Centers for Disease Control and Prevention, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America. December 2015. Available at <a href=\"http://aidsinfo.nih.gov/contentfiles/lvguidelines/adult_oi.pdf\" target=\"_blank\">http://aidsinfo.nih.gov/contentfiles/lvguidelines/adult_oi.pdf</a>. Accessed March 17, 2016</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Mathad JS, Gupta A. Tuberculosis in pregnant and postpartum women: epidemiology, management, and research gaps. <i>Clin Infect Dis</i>. 2012;55(11):1532-1549.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/isoniazid-pediatric-drug-information/abstract-text/22942202/pubmed\" target=\"_blank\" id=\"22942202\">22942202</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Miki M, Ishikawa T, Okayama H. An outbreak of histamine poisoning after ingestion of the ground saury paste in eight patients taking isoniazid in tuberculous ward. <i>Intern Med</i>. 2005;44(11):1133-1136.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/isoniazid-pediatric-drug-information/abstract-text/16357449/pubmed\" target=\"_blank\" id=\"16357449\">16357449</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Nahid P, Dorman SE, Alipanah N, et al. Official American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America Clinical Practice Guidelines: Treatment of drug-susceptible tuberculosis. <i>Clin Infect Dis</i>. 2016;63(7):e147-195.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/isoniazid-pediatric-drug-information/abstract-text/27516382/pubmed\" target=\"_blank\" id=\"27516382\">27516382</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Self TH, Chrisman CR, Baciewicz AM, Bronze MS. Isoniazid drug and food interactions. <i>Am J Med Sci</i>. 1999;317(5):304-311.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/isoniazid-pediatric-drug-information/abstract-text/10334118/pubmed\" target=\"_blank\" id=\"10334118\">10334118</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Starke JR, &ldquo;Modern Approach to the Diagnosis and Treatment of Tuberculosis in Children,&rdquo; <i>Pediatr Clin North Am</i>, 1988, 35(3):441-64.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/isoniazid-pediatric-drug-information/abstract-text/3287309/pubmed\" target=\"_blank\" id=\"3287309\">3287309</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Starke JR, &ldquo;Multidrug Therapy for Tuberculosis in Children,&rdquo; <i>Pediatr Infect Dis J</i>, 1990, 9(11):785-93.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/isoniazid-pediatric-drug-information/abstract-text/2124671/pubmed\" target=\"_blank\" id=\"2124671\">2124671</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Toutoungi M, Carroll RL, Enrico JF, Perey L. Cheese, wine, and isoniazid. <i>Lancet</i>. 1985;2(8456):671.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/isoniazid-pediatric-drug-information/abstract-text/2863660/pubmed\" target=\"_blank\" id=\"2863660\">2863660</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Van Scoy RE and Wilkowske CJ, &ldquo;Antituberculous Agents: Isoniazid, Rifampin, Streptomycin, Ethambutol, and Pyrazinamide,&rdquo; <i>Mayo Clin Proc</i>, 1983, 58(4):233-40.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/isoniazid-pediatric-drug-information/abstract-text/6834890 /pubmed\" target=\"_blank\" id=\"6834890 \">6834890 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    World Health Organization (WHO). G<i>uidance for National Tuberculosis Programmes on the Management of Tuberculosis in Children</i>. 2nd ed. Geneva, Switzerland: WHO Document Production Services; 2014.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    World Health Organization (WHO). <i>Treatment of Tuberculosis Guidelines</i>. 4th ed. Geneva, Switzerland: WHO Press; 2010.</div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 13393 Version 151.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"ALERT: US Boxed Warning\" href=\"#F5708956\" class=\"outlineLink\">ALERT: US Boxed Warning</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F184784\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Therapeutic Category\" href=\"#F1048065\" class=\"outlineLink\">Therapeutic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Usual\" href=\"#F1048057\" class=\"outlineLink\">Dosing: Usual</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F184755\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Availability (US)\" href=\"#F184739\" class=\"outlineLink\">Generic Availability (US)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F1048069\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Storage/Stability\" href=\"#F184778\" class=\"outlineLink\">Storage/Stability</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F1048068\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F3271336\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F184829\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F184763\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F184743\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F184818\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F184748\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Food Interactions\" href=\"#F184779\" class=\"outlineLink\">Food Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Risk Factor\" href=\"#F184751\" class=\"outlineLink\">Pregnancy Risk Factor</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F184767\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F1048064\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F184742\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics (Adult data unless noted)\" href=\"#F184762\" class=\"outlineLink\">Pharmacodynamics/Kinetics (Adult data unless noted)</a></li><li class=\"plainItem\"><a sectionName=\"Extemporaneous Preparations\" href=\"#F184761\" class=\"outlineLink\">Extemporaneous Preparations</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F184766\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F184770\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_PED/13393|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=isoniazid-drug-information\" class=\"drug drug_general\">Isoniazid: Drug information</a></li><li><a href=\"topic.htm?path=isoniazid-patient-drug-information\" class=\"drug drug_patient\">Isoniazid: Patient drug information</a></li></ul></div></div>","javascript":null}